Envestnet Portfolio Solutions Inc. increased its position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 42.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,959 shares of the company's stock after buying an additional 26,344 shares during the period. Envestnet Portfolio Solutions Inc. owned 0.07% of Henry Schein worth $6,498,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its stake in shares of Henry Schein by 6.5% in the 1st quarter. JPMorgan Chase & Co. now owns 6,373,036 shares of the company's stock valued at $436,489,000 after buying an additional 390,399 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Henry Schein by 4.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,240,933 shares of the company's stock valued at $153,480,000 after buying an additional 103,384 shares during the period. Burgundy Asset Management Ltd. grew its stake in shares of Henry Schein by 33.9% in the 1st quarter. Burgundy Asset Management Ltd. now owns 2,235,429 shares of the company's stock valued at $153,105,000 after buying an additional 566,530 shares during the period. Clarkston Capital Partners LLC grew its stake in shares of Henry Schein by 0.4% in the 1st quarter. Clarkston Capital Partners LLC now owns 1,751,570 shares of the company's stock valued at $119,965,000 after buying an additional 7,345 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Henry Schein by 1.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,203,676 shares of the company's stock valued at $82,440,000 after buying an additional 11,999 shares during the period. 96.62% of the stock is currently owned by institutional investors and hedge funds.
Henry Schein Stock Up 0.6%
Shares of NASDAQ:HSIC opened at $63.39 on Wednesday. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.49. The firm has a fifty day moving average of $67.31 and a 200 day moving average of $68.72. The firm has a market capitalization of $7.69 billion, a PE ratio of 20.45, a price-to-earnings-growth ratio of 2.08 and a beta of 0.81. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41.
Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.09). Henry Schein had a return on equity of 14.36% and a net margin of 3.05%.The company had revenue of $3.24 billion during the quarter, compared to analysts' expectations of $3.22 billion. During the same quarter last year, the firm posted $1.23 earnings per share. The firm's revenue was up 3.3% on a year-over-year basis. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. As a group, research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the company. Barrington Research reiterated an "outperform" rating and set a $78.00 price target on shares of Henry Schein in a research note on Tuesday, September 23rd. Leerink Partners set a $75.00 target price on shares of Henry Schein in a research report on Monday, July 14th. Wall Street Zen cut shares of Henry Schein from a "buy" rating to a "hold" rating in a research report on Saturday. Robert W. Baird reissued a "neutral" rating and set a $72.00 target price (down previously from $82.00) on shares of Henry Schein in a research report on Monday, July 14th. Finally, Stifel Nicolaus reissued a "hold" rating and set a $75.00 target price (down previously from $80.00) on shares of Henry Schein in a research report on Friday, July 25th. Five analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $76.67.
Get Our Latest Research Report on Henry Schein
Henry Schein Profile
(
Free Report)
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Recommended Stories
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Henry Schein, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.
While Henry Schein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.